We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.

Delisted

ITCI was delisted on the 1st of April, 2025.

55 hedge funds and large institutions have $204M invested in Intra-Cellular Therapies Inc. in 2014 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 8

129% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 7

57% more funds holding

Funds holding: 3555 (+20)

2% more capital invested

Capital invested by funds: $201M → $204M (+$3.12M)

Holders
55
Holders Change
+20
Holders Change %
+57.14%
% of All Funds
1.58%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
29
Increased
16
Reduced
7
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
VFA
51
Virtus Fund Advisers
Connecticut
$25K +$24.1K +1,459 New
Wells Fargo
52
Wells Fargo
California
$21K +$20.1K +1,217 New
Teacher Retirement System of Texas
53
Teacher Retirement System of Texas
Texas
$11K +$11.2K +675 New
Barclays
54
Barclays
United Kingdom
$7K +$5.09K +308 +308%
Citigroup
55
Citigroup
New York
$2K +$2.38K +144 New
BC
56
Broadfin Capital
New York
-$4.08M -224,234 Closed
DM
57
Deerfield Management
New York
-$3.12M -171,437 Closed
AC
58
Ascend Capital
California
-$1.48M -81,231 Closed
HCMT
59
Highland Capital Management (Texas)
Texas
-$487K -26,809 Closed
EEG
60
E.E. Geduld
-$364K -20,030 Closed
Tudor Investment Corp
61
Tudor Investment Corp
Connecticut
-$364K -20,000 Closed
SCA
62
SAC Capital Advisors
Connecticut
-$348K -19,139 Closed
U
63
UBS
Switzerland
-$33K -1,842 Closed

ITCI Hedge Fund Activity: Q2 2014 in Review

55 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2014, worth a combined $204M — up 1.6% from $201M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ITCI positions and 8 closed out — a net gain of 21 holders — while 16 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $6.97M. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.08M sold.

  • 55 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2014, up from 35 in Q1 2014.
  • Funds reported $204M of Intra-Cellular Therapies Inc. stock for Q2 2014, up 1.6% quarter-over-quarter.
  • 29 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2014 and 8 closed out, a net change of +21 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $6.97M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2014 was Broadfin Capital, an estimated $4.08M sold.

Based on aggregated 13F filings for Q2 2014.